This is a real-world medical entrance exam question, please give the true answer based on the question and selection. Topic name: Psoriasis, Subject name: Dental
[{'content': 'Ixekizumab is novel drug approved by the FDA for treatment of psoriasis, MOA of this drug is : \nSelect and explain. \nA. IL-17A agonist, B. IL-17A antagonist, C. IL-12/23 antagonist, D. PDE 4 inhibitor', 'role': 'user'}, {'content': 'Answer: B \nExplanation: Ixekizumab, approved for treatment of plaque psoriasis. It is a humanized IL-17A antagonist that works when IgG4 monoclonal antibodies selectively bind with IL-17A cytokines and inhibit their interaction with the IL-17 receptor. Secukinumab, similar to Ixekizumab, this injectable is an IgG1 monoclonal antibody that selectively binds to the IL-17A cytokine and inhibits its interaction with the IL-17 receptor. It is approved for the treatment of plaque psoriasis and psoriatic ahritis. Ustekinumab : Anti IL-12/23 Apremilast: PDE-4 inhibitor', 'role': 'assistant'}]